Besides, tumor-specific methylation of ZFP82 has been implicated in multiple myeloma, with studies suggesting their potential as epigenetic biomarkers for the diagnosis of multiple myeloma as well as a promising target for specific treatment (Fan et al., 2016). This evidence concerns the gene ZFP82 and neoplasm.